TICKERNERD
Menu
KAPAKAPAHealthcare · Biotechnology

KAPA Stock Forecast: Kairos Pharma Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.29
−1.69% on the day

The 2 Wall Street analysts covering Kairos Pharma Ltd. hold a median 12-month price target of $7 — +2313.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.9M
Ticker Nerd rank
38 / 100
Median analyst target
$7.00
Analysts covering
2
Total return, dividends reinvested
1W
−15.0%
1M
−19.0%
YTD
−59.2%
1Y
−75.2%
From 52W high
−85.3%
From 52W low
+1.8%
$0.29
$1.97
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KAPA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kairos Pharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Accruals
78
Growth
59
Revisions
53
Issuance
35
Quality
32
Value
26
Volatility
23
Momentum
6

Size (95): Smaller than most of the companies we track.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KAPA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KAPA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26KAPAHigh $12.00Median $7.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $2.00Median $7.00High $12.00

The green dot is the last close — the median target sits +2313.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Nov 2025D. Boral CapitalMaintainsBuy—
4 Nov 2025D. Boral CapitalMaintainsBuy—
20 Oct 2025D. Boral CapitalMaintainsBuy—
7 Oct 2025D. Boral CapitalMaintainsBuy—
19 Sept 2025D. Boral CapitalMaintainsBuy—
16 July 2025D. Boral CapitalMaintainsBuy—
4 June 2025D. Boral CapitalMaintainsBuy—
17 Apr 2025D. Boral CapitalMaintainsBuy—
3 Apr 2025HC Wainwright & Co.InitiatesBuy—
31 Mar 2025D. Boral CapitalMaintainsBuy—
27 Mar 2025Maxim GroupInitiatesBuy—
20 Mar 2025D. Boral CapitalMaintainsBuy—
26 Feb 2025D. Boral CapitalMaintainsBuy—
18 Feb 2025D. Boral CapitalMaintainsBuy—
12 Feb 2025D. Boral CapitalMaintainsBuy—
22 Jan 2025D. Boral CapitalMaintainsBuy—
14 Nov 2024D. Boral CapitalMaintainsBuy—
14 Oct 2024EF HuttonInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KAPA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KAPA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Kairos Pharma Ltd. (KAPA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.0×

Cheaper than 82% of US stocks

Price / sales
—
Price / book
1.5×

Cheaper than 57% of US stocks

EV / EBITDA
−0.7×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−114.0%

Higher than 12% of US stocks

Return on assets
−66.9%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KAPA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KAPAKairos Pharma Ltd.$6.9M
38
LIMNLiminatus Pharma, Inc.$6.9M
10
NIKINiki Biosolutions, Inc.$7.0M
12
BOLTBolt Biotherapeutics, Inc.$7.0M
73
ENSCEnsysce Biosciences, Inc.$7.3M
41
XCURExicure, Inc.$7.3M
46
ENVBEnveric Biosciences, Inc.$6.4M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kairos Pharma Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KAPA news & analysis

Kairos Pharma Announces 1-for-7 Reverse Stock Split

Business Wire · 21 Aug 2026neutral

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced a 1-for-7 reverse stock split of its outstanding common shares. The split is expected to become effective on September 1, 2026 at 12:01 a.m. ET, with shares expected to begin trading on the NYSE American on a split-adjusted basis at that time.

Why it matters — A reverse stock split will consolidate Kairos Pharma's outstanding shares, changing its share count and per-share price, which matters to shareholders tracking the company's capital structure.

FAQ

Frequently asked questions about KAPA stock

What is the KAPA stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Kairos Pharma Ltd. have a median 12-month price target of $7, with estimates ranging from $2 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KAPA stock a buy right now?

Of the 2 analysts covering Kairos Pharma Ltd., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kairos Pharma Ltd. 38 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KAPA?

As at 22 Aug 2026, Kairos Pharma Ltd. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will KAPA stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +2313.8% from the last close, and Ticker Nerd's factor model ranks Kairos Pharma Ltd. 38 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KAPA stock forecast for 2030?

No analyst covering Kairos Pharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KAPA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $12 over the next 12 months.

How has KAPA stock performed over the past year?

Kairos Pharma Ltd. returned -75.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kairos Pharma Ltd. do?

Kairos Pharma Ltd. is a pharmaceutical company focused on the research, development, and commercialization of innovative therapies.

What is the latest news on KAPA?

The most recent item we track (Business Wire, 21 Aug 2026): "Kairos Pharma Announces 1-for-7 Reverse Stock Split". Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced a 1-for-7 reverse stock split of its outstanding common shares. The split is expected to become effective on September 1, 2026 at 12:01 a.m. ET, with shares expected to begin trading on the NYSE American on a split-adjusted basis at that time.

Company

About Kairos Pharma Ltd.

Kairos Pharma Ltd. is a pharmaceutical company focused on the research, development, and commercialization of innovative therapies. Its primary function is to advance treatments that target niche, unmet medical needs, particularly in the fields of oncology and degenerative diseases. The company is committed to harnessing cutting-edge scientific advancements and biotechnology, working alongside healthcare professionals and researchers to bring viable solutions to the market. Notable features include its robust pipeline of clinical trials that explore novel drug candidates and proprietary platforms aimed at improving patient outcomes. Kairos Pharma Ltd. plays a pivotal role in the healthcare sector, contributing to the development of new medications that offer hope to patients and healthcare providers alike. By addressing specialized medical demands, the company influences the pharmaceutical landscape and supports the ongoing evolution of targeted therapies.

CEO Dr. John S. Yu M.D., Ph.D. · 1 employees · United States · https://kairospharma.com